Enable Injections picks up $30M to commercialize its drug-delivering patch

Enable 10 mL Injector--Courtesy of Enable Injections

Enable Injections closed a $30 million Series A round, which will go toward commercializing its adhesive drug-delivering patch aimed at reducing pain and error when self-delivering drugs.

The Enable Injector adheres to the body and delivers subcutaneous doses of biologics, such as insulin, comfortably. The patient pushes a button and the device inserts a needle, delivers the drug and, upon removal, retracts the needle. The flow of the drug being delivered adapts to each individual user, and the device has a pause function, allowing the patient to take a break at any time, the company said. It is available in a range of volumes from 5 mL to 50 mL.

Most biologics must be delivered in doses greater than 5 mL, but the typical syringe dose is 1 mL, the company said in a statement. And while delivering biologics subcutaneously is preferred, current tech doesn’t allow that, the company said.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

“The Enable injector has the potential to transform the delivery of a significant and growing category of drugs,” said Bob Coy, CEO of CincyTech, which participated in financing, in the statement. “It offers comfort and convenience to patients, a point of differentiation to pharmaceutical companies, and a reduction of costs to the health care system."

ORI Healthcare Fund led the financing, with participation from CincyTech, Cincinnati Children’s Hospital, CintriFuse and the Ohio Innovation Fund. Enable Injections is also developing vial and syringe transfer systems to move a drug into its Enable Injector.

Suggested Articles

By employing heart rate signals, physical activity and sleep quality, common Fitbit trackers may be able to predict the spread of the flu.

Nanox has raised $26 million to help fuel the development and commercialization of its Star Trek-inspired digital X-ray bed.

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.